Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INDP Indaptus Therapeutics, Inc.

Trading 12-23 11:18:25 EST

0.9400

+0.0020

+0.21%

High0.9400	Low0.9127	Vol10.53K
Open0.9127	D1 Closing0.9380	Amplitude2.91%
Mkt Cap11.29M	Tradable Cap8.74M	Total Shares12.01M
T/O9.77K	T/O Rate0.11%	Tradable Shares9.29M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"INDP","market":"US","secType":"STK","nameCN":"Indaptus Therapeutics, Inc.","latestPrice":0.94,"timestamp":1734970638802,"preClose":0.938,"halted":0,"volume":10528,"delay":0,"floatShares":9294000,"shares":12013901,"eps":-1.707073,"marketStatus":"Trading","change":0.002,"latestTime":"12-23 11:18:25 EST","open":0.9127,"high":0.94,"low":0.9127,"amount":9769.47476064,"amplitude":0.029104,"askPrice":1.02,"askSize":100,"bidPrice":0.89,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.707073,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1734987600000},"marketStatusCode":2,"adr":0,"listingDate":1438660800000,"exchange":"NASDAQ","adjPreClose":0.938,"preHourTrading":{"tag":"盘前","latestPrice":1.02,"preClose":0.938,"latestTime":"08:29 EST","volume":187,"amount":190.7598968,"timestamp":1734960542008},"postHourTrading":{"tag":"盘后","latestPrice":0.938,"preClose":0.938,"latestTime":"17:18 EST","volume":19,"amount":17.467,"timestamp":1734733132650},"volumeRatio":1.549896},"requestUrl":"/m/hq/s/INDP/wiki","defaultTab":"wiki","newsList":[{"id":"2485265999","title":"BRIEF-Indaptus Therapeutics Announces $2.135 Million Registered Direct Offering And Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2485265999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485265999?lang=en_us&edition=fundamental","pubTime":"2024-11-22 22:00","pubTimestamp":1732284031,"startTime":"0","endTime":"0","summary":"BRIEF-Indaptus Therapeutics Announces $2.135 Million Registered Direct Offering And Concurrent Private PlacementNov 22 (Reuters) - Indaptus Therapeutics Inc INDP.O:INDAPTUS THERAPEUTICS, INC. ANNOUNCE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nTUACFJS3J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"gpt_icon":0},{"id":"2485638952","title":"Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2485638952","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485638952?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:36","pubTimestamp":1732282574,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nTUACFJS3J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2483504021","title":"U.S. RESEARCH ROUNDUP- AMN Healthcare Services, Chart Industries, Home Depot","url":"https://stock-news.laohu8.com/highlight/detail?id=2483504021","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483504021?lang=en_us&edition=fundamental","pubTime":"2024-11-13 15:03","pubTimestamp":1731481390,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AMN Healthcare Services, Chart Industries and Home Depot, on Wedn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4224","EWTX","LNW","NUVL","AXSM","FATE","IBP","HCAR","LU1093756168.USD","BLFS","BK4539","HSBC","LEGN","LU0354030511.USD","LU2065171402.SGD","PTVE","ATLC","PALI","COLD","DAY","STIM","DCOM","BK4533","LU0820562030.AUD","PRME","INDP","NVAX","PT","LU0683600562.USD","AMN","LU1430594728.SGD","ICUI","BHVN","BK4209","BBIO","LINE","GTLS","HRTX","BMY","CART","KZR","IAC","SATS","EVCM","SHOP","MOS","CAVA","ITOS","HD","HON"],"gpt_icon":1},{"id":"2483048154","title":"Indaptus Therapeutics Inc :  Maxim Group Cuts Target Price to $5 From $8","url":"https://stock-news.laohu8.com/highlight/detail?id=2483048154","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483048154?lang=en_us&edition=fundamental","pubTime":"2024-11-13 12:50","pubTimestamp":1731473429,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nFWN3MJ1FX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2482817237","title":"Indaptus Therapeutics publishes research in Frontiers in Immunology","url":"https://stock-news.laohu8.com/highlight/detail?id=2482817237","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482817237?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:30","pubTimestamp":1731331846,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics (INDP) announced that Dr. Michael Newman, Founder and Chief Scientific Officer, has published his research in the peer-review...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/indaptus-therapeutics-publishes-research-in-frontiers-in-immunology?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/indaptus-therapeutics-publishes-research-in-frontiers-in-immunology?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","INDP"],"gpt_icon":0},{"id":"2481014419","title":"Indaptus Therapeutics Presents Encouraging Interim Safety Data From Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2481014419","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481014419?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUA2WVDN0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INDP","BK4139"],"gpt_icon":0},{"id":"2481904186","title":"Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2481904186","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481904186?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984400,"startTime":"0","endTime":"0","summary":"Data further confirms Company’s “Pulse-Prime” hypothesis. NEW YORK, Nov. 07, 2024  -- Indaptus Therapeutics, Inc.  , a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces compelling safety, pharmacokinetics, and biomarker data on its lead compound, Decoy20, at the Society for Immunotherapy of Cancer  2024 annual meeting. The data derive from two cohorts  of Decoy20 single administration and one cohort  of Decoy20 weekly administration in the Company’s ongoing Phase 1 clinical trial. The SITC conference is being held November 6-10, 2024 in Houston, Tex.Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be adminis","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3XXQS3YWdGJ1JC2JJgEReg--~B/aD02MDt3PTIyNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/7ccb73735e7b3453e7f55361e2fdf8ed","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3XXQS3YWdGJ1JC2JJgEReg--~B/aD02MDt3PTIyNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/7ccb73735e7b3453e7f55361e2fdf8ed"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/indaptus-therapeutics-presents-encouraging-interim-130000687.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NLR","LENZ","BK4080","BK4139","BK4231","INDP","SITC"],"gpt_icon":0},{"id":"2477262369","title":"Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2477262369","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477262369?lang=en_us&edition=fundamental","pubTime":"2024-10-23 02:24","pubTimestamp":1729621440,"startTime":"0","endTime":"0","summary":"Shares of Indaptus Therapeutics rose after the company said it reached an agreement with BeiGene to evaluate novel cancer treatment combinations.The stock gained 14% to $1.68 in afternoon trading Tuesday. Shares are down 6.8% since the beginning of the year.Under Indaptus' clinical supply agreement with BeiGene, the New York biotechnology company plans to advance human clinical evaluation of its cancer treatment -- called Decoy20, which is being studied as a treatment for various cancers, such as liver, colon and pancreatic -- in combination with BeiGene's anti-PD-1 antibody, called tislelizumab.Preclinical studies showed that Decoy20, when used in combination with a PD-1 inhibitor and an oral non-steroidal anti-inflammatory agent, demonstrated tumor eradication rates of between 80% and 100%, Indaptus said.Terms of the agreement weren't disclosed. As part of the pact, BeiGene will provide Indaptus with access to its PD-1 inhibitor, as well as provide technical expertise to accelerate t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","BK4505","BK4504","BK4548","BK1161","BK1500","BK4588","BGNE","LU2328871848.SGD","BK4585","BK4139","BK4535","LENZ","LU1969619763.USD","BK1583","LU0307460666.USD","INDP","BK4526","LU0588546209.SGD","BK1588"],"gpt_icon":0},{"id":"2477836651","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2477836651","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477836651?lang=en_us&edition=fundamental","pubTime":"2024-10-23 01:52","pubTimestamp":1729619568,"startTime":"0","endTime":"0","summary":"Mueller Industries (MLI) reported a year-over-year increase in fiscal Q3 adjusted diluted earnings and net sales late Monday.Shares jumped 16%, with intraday trading volume at over 1.17 million compar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GM","LU0130102774.USD","LU0130518102.USD","LU0477156953.USD","LU0208291251.USD","BK4555","LU0648000940.SGD","LU0345770308.USD","LU0070302665.USD","BK4561","LU0345770993.USD","BK4139","LU0072461881.USD","BK4504","BK4548","BGNE","BK4559","BK4566","LU0006061336.USD","LU1201861249.SGD","LU0477156797.USD","BK4099","LU0162691827.USD","LU0980610538.SGD","BK4161","LU0130517989.USD","BK4574","LU0648001328.SGD","LU0211331839.USD","BK4516","LU0320765489.SGD","MLI","BK4505","LU1201861165.SGD","BK4535","INDP","BK4585","BK4588","BK4526","LU0130103400.USD"],"gpt_icon":0},{"id":"2477583343","title":"Indaptus Therapeutics signs clinical supply agreement with Beigene","url":"https://stock-news.laohu8.com/highlight/detail?id=2477583343","media":"seekingalpha","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477583343?lang=en_us&edition=fundamental","pubTime":"2024-10-22 21:34","pubTimestamp":1729604059,"startTime":"0","endTime":"0","summary":"Eoneren/E+ via Getty Images  Indaptus Therapeutics  announced a clinical supply agreement with BeiGene  . Indaptus plans to advance human clinical evaluation of the combination of BeiGene's anti-PD-1 antibody, tislelizumab, with Indaptus’ Decoy20, a novel treatment designed to induce a broad immune response to fight cancer.","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346213103/image_1346213103.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346213103/image_1346213103.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4189766-indaptus-therapeutics-signs-clinical-supply-agreement-with-beigene","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK1500","BK1161","BK4139","NQmain","LENZ","LU2328871848.SGD","QID","QLD",".IXIC","BK4505","LU1969619763.USD","SQQQ","BK1588","06160","LU0307460666.USD","BK4588","TQQQ","LU0588546209.SGD","BK4504","BK4535","BK4526","BK4548","PSQ","BK1583","BK4585","MNQmain","INDP","BGNE"],"gpt_icon":0},{"id":"2477228336","title":"BRIEF-Indaptus Therapeutics Announces Clinical Supply Agreement With Beigene To Evaluate Novel Cancer Treatment Combinations","url":"https://stock-news.laohu8.com/highlight/detail?id=2477228336","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477228336?lang=en_us&edition=fundamental","pubTime":"2024-10-22 20:40","pubTimestamp":1729600830,"startTime":"0","endTime":"0","summary":"Oct 22  - Indaptus Therapeutics Inc   :   * INDAPTUS THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH BEIGENE TO EVALUATE NOVEL CANCER TREATMENT COMBINATIONS   * INDAPTUS THERAPEUTICS INC - INDUSTRY FIRST CLINICAL TRIAL COMBINING TISLELIZUMAB AND DECOY20 EXPECTED  TO START IN 2025Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BGNE","INDP","LENZ"],"gpt_icon":0},{"id":"2477338722","title":"Indaptus Therapeutics Announces Clinical Supply Agreement With Beigene to Evaluate Novel Cancer Treatment Combinations","url":"https://stock-news.laohu8.com/highlight/detail?id=2477338722","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477338722?lang=en_us&edition=fundamental","pubTime":"2024-10-22 20:00","pubTimestamp":1729598402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241022:nTUABHJV7S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2477338083","title":"Indaptus Therapeutics Inc - Industry First Clinical Trial Combining Tislelizumab and Decoy20 Expected  to Start in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2477338083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477338083?lang=en_us&edition=fundamental","pubTime":"2024-10-22 20:00","pubTimestamp":1729598402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241022:nTUABHJV7S:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2475966736","title":"Indaptus Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2475966736","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475966736?lang=en_us&edition=fundamental","pubTime":"2024-10-16 19:15","pubTimestamp":1729077300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/INDP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 16, 2024 07:15 ET (11:15 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","LENZ"],"gpt_icon":0},{"id":"2475920508","title":"Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2475920508","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475920508?lang=en_us&edition=fundamental","pubTime":"2024-10-15 20:00","pubTimestamp":1728993602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241015:nTUACFST5N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2467153791","title":"Indaptus Therapeutics files to sell 1.64M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2467153791","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467153791?lang=en_us&edition=fundamental","pubTime":"2024-09-13 12:53","pubTimestamp":1726203220,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics (NASDAQ:INDP) filed a prospectus related to the offer and resale by the selling stockholders of up to 1,643,837 shares of common stock.\nThe warrants were issued and sold to accredited investors in a private placement  which closed on August 8, 2024.","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346675513/image_1346675513.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346675513/image_1346675513.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4149312-indaptus-therapeutics-files-to-sell-164m-shares-of-common-stock-for-holders","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139",".IXIC","INDP","TQQQ","NQmain","QID","LENZ","MNQmain","PSQ","QLD","SQQQ"],"gpt_icon":1},{"id":"2465546889","title":"Indaptus Therapeutics Inc: Initiate Dosing Patients at Higher Decoy20 Dose on a Weekly Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2465546889","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465546889?lang=en_us&edition=fundamental","pubTime":"2024-09-05 20:30","pubTimestamp":1725539402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240905:nTUA8SXN22:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2465450265","title":"Indaptus Therapeutics Inc: Safety Profile Being Observed to Date Continues to Be Consistent With Decoy20's Mechanism of Action","url":"https://stock-news.laohu8.com/highlight/detail?id=2465450265","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465450265?lang=en_us&edition=fundamental","pubTime":"2024-09-05 20:30","pubTimestamp":1725539402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240905:nTUA8SXN22:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INDP","BK4139"],"gpt_icon":0},{"id":"2465154576","title":"Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses","url":"https://stock-news.laohu8.com/highlight/detail?id=2465154576","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465154576?lang=en_us&edition=fundamental","pubTime":"2024-09-05 20:30","pubTimestamp":1725539402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240905:nTUA8SXN22:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INDP","BK4139"],"gpt_icon":0},{"id":"2465012545","title":"Indaptus Therapeutics Inc: Continue Dosing Additional Patients at Lower Decoy20 Dose on a Weekly Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2465012545","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465012545?lang=en_us&edition=fundamental","pubTime":"2024-09-05 20:30","pubTimestamp":1725539402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240905:nTUA8SXN22:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.indaptusrx.com","stockEarnings":[{"period":"1week","weight":-0.062},{"period":"1month","weight":-0.1151},{"period":"3month","weight":-0.3348},{"period":"6month","weight":-0.5831},{"period":"1year","weight":-0.4956},{"period":"ytd","weight":-0.467}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.027434},{"month":2,"riseRate":0.444444,"avgChangeRate":0.014519},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.025686},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.016408},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.032542},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.014205},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.050227},{"month":8,"riseRate":0.444444,"avgChangeRate":0.063432},{"month":9,"riseRate":0.4,"avgChangeRate":-0.005204},{"month":10,"riseRate":0.2,"avgChangeRate":-0.111809},{"month":11,"riseRate":0.3,"avgChangeRate":-0.032067},{"month":12,"riseRate":0.4,"avgChangeRate":-0.050349}],"exchange":"NASDAQ","name":"Indaptus Therapeutics, Inc.","nameEN":"Indaptus Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Indaptus Therapeutics, Inc.(INDP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Indaptus Therapeutics, Inc.,INDP,Indaptus Therapeutics, Inc.股票,Indaptus Therapeutics, Inc.股票老虎,Indaptus Therapeutics, Inc.股票老虎国际,Indaptus Therapeutics, Inc.行情,Indaptus Therapeutics, Inc.股票行情,Indaptus Therapeutics, Inc.股价,Indaptus Therapeutics, Inc.股市,Indaptus Therapeutics, Inc.股票价格,Indaptus Therapeutics, Inc.股票交易,Indaptus Therapeutics, Inc.股票购买,Indaptus Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Indaptus Therapeutics, Inc.(INDP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}